What is Zacks Research’s Estimate for ORMP Q2 Earnings?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Equities research analysts at Zacks Research issued their Q2 2026 EPS estimates for Oramed Pharmaceuticals in a note issued to investors on Monday, June 8th. Zacks Research analyst M. Marin expects that the biotechnology company will post earnings of $0.15 per share for the quarter. Zacks Research also issued estimates for Oramed Pharmaceuticals’ Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.24 EPS and FY2026 earnings at $0.71 EPS.

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Friday, March 27th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Oramed Pharmaceuticals presently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Stock Performance

Oramed Pharmaceuticals stock opened at $3.70 on Thursday. Oramed Pharmaceuticals has a 1 year low of $1.98 and a 1 year high of $5.01. The firm has a 50 day moving average price of $3.90 and a 200 day moving average price of $3.46. The company has a market cap of $151.43 million, a price-to-earnings ratio of 1.43 and a beta of 1.26.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its earnings results on Friday, March 27th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Kathmere Capital Management LLC purchased a new stake in Oramed Pharmaceuticals during the first quarter worth approximately $51,000. OMERS ADMINISTRATION Corp purchased a new stake in Oramed Pharmaceuticals during the first quarter worth approximately $63,000. Redwood Family Wealth LLC purchased a new stake in Oramed Pharmaceuticals during the fourth quarter worth approximately $66,000. XTX Topco Ltd grew its stake in Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after buying an additional 14,297 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in Oramed Pharmaceuticals during the fourth quarter worth approximately $119,000. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.